Skip to main content
Premium Trial:

Request an Annual Quote

Reg Jones, Steve Martin, Cristopher McReynolds, Ferdinand Verdonck, Harrold van Barlingen, Ronald Brus, Stephen Bunting, Steven Burrill, Dirk Pollet, Russell Bradley, Gregory Gosch, and more


Reg Jones will retire as chief financial officer of Stratagene, effective June 30, the company said last week. Jones, who will remain a company consultant, will be replaced by Steve Martin, the company's director of finance. Prior to joining Stratagene a year ago, he was the controller of GenProbe.

Cristopher McReynolds joined Galapagos of Belgium last month as director of business development for Galapagos and its subsidiary Galadeno in the US, GenomeWeb News, Pharmacogenomics Reporter's sister publication, has learned. Most recently, he was vice president of business development at Cepheid. McReynolds holds MBA and a BSc in biology and zoology.

In addition, Ferdinand Verdonck has become an independent director, and Harrold van Barlingen a director of Galapagos, the company said on Monday. Four other directors, Ronald Brus, Stephen Bunting, Steven Burrill, and Dirk Pollet, stepped down from the board.

Verdonck was most recently managing director of Almanij. He holds a law degree and an economics degree from the University of Leuven in Belgium and a degree in economics from the University of Chicago. Barlingen heads life science investments at AlpInvest Partners. He holds a PhD in cardiovascular diseases and an MSc in medical biology from the University of Utrecht in the Netherlands.

The board changes result from Galapagos' listing on the Euronext stock exchange, according to the company.

Russell Bradley has become vice president of business development and strategic planning of Luminex, the Austin, Texas-based company said on Monday. In addition, Gregory Gosch has become vice president of marketing and sales, and Randel Marfin vice president of the Luminex Bioscience Group, a new position.

Most recently, Bradley was director of Beckman Coulter's Cares initiative. He holds a bachelor of science degree in immunology and biochemistry from Monash University in Australia.

Douglas Freedman has become a director, and Steve Slilaty head of an advisory board of Pacific Sunset Investments, the Huntington Beach, Calif.-based company said last week. Pacific Sunset recently acquired Gen-ID Lab Services, a company specializing in SNP analysis data. Slilaty, who is the chief scientific officer and president of Advanomics, will help the company review new SNP technologies.

Paul Stinson, director general of the Human Proteome Organization, has made four hires for the new HUPO secretariat in Montreal, ProteoMonitor, a GenomeWeb newsletter, reported last week. Wehbeh Barghachie will serve as congress director and project manager; Elizabeth Cooper has become communications and industry liaison manager; Sandrine Palcy will be training coordinator; and Sylvie Ouellette will serve as the membership and administration coordinator.

Roger Wiegand has become director of the infectious disease initiative at the Broad Institute, GenomeWeb News, Pharmacogenomics Reporter's sister publication, has learned. Prior to joining the Broad, he was chief scientific officer of Cantata Laboratories in Cambridge, Mass.

Filed under

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.